Ceribell president and CEO Chao Xingjuan sells $521,775 in stock

President and CEO of Ceribell, Chao Xingjuan, sold 20,846 shares of the company's common stock on September 15, 2026, for a total of $521,775. The shares were traded at prices varying from $25 to $25.12, with an average price of $25.03 per share. The sale occurred as Ceribell's stock price hovered near its 52-week peak of $25.63, following a substantial 99% increase over the past year.

According to InvestingPro analysis, the stock appears overvalued compared to its Fair Value, ranking among the most overvalued stocks in the market. The transaction was conducted under a Rule 10b5-1 trading plan that Ms. Chao established on September 12, 2025. Following this sale, Ms. Chao personally owns 746,345 shares of Ceribell common stock, with an additional 369,088 shares indirectly held by the ACP 2021 Trust, of which she is a co-trustee.

Ms. Chao disclaims any beneficial ownership of the indirectly held securities except for her financial interest in them.

Recently, Ceribell reported a second-quarter revenue of $28.1 million for fiscal 2026, a 33% increase compared to the previous year. However, the company reported a loss of $0.51 per share, which surpassed analysts' expectations of a $0.36 loss. In response, Canaccord raised its price target on Ceribell shares to $26, maintaining a Buy rating, highlighting strong same-store utilization as a growth driver.

BTIG also increased its price target to $30 from $28, emphasizing Ceribell's leadership in point-of-care rapid EEG and its recent FDA approval for expanded indications. Raymond James raised its price target to $29, noting new growth drivers expected to enhance utilization and improve consensus estimates. These developments signify Ceribell's continuous expansion and innovative strides in the medical device industry.